AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2025 Issue 1; Section X – New Technology

Administration of Emapalumab-lzsg

In table XW0, Introduction of Anatomical Regions, substance values M emapalumab-lzsg Anti-IFNy monoclonal antibody, and N tarlatamab-dlle, were added to the body part values 3 Peripheral Vein and 4 Central Vein.Body Part Approach Device/Substance/Technology Qualifier 3 Peripheral Vein 4 Central Vein 3 Percutaneous M Emapalumab-lzsg Anti-IFNy Monoclonal Antibody N Tarlatamab-dlle Antineoplastic A New Technology Group 10 Emapalumab-Izsg is an interferon gamma (IFNy)-blocking antibody that is indicated in the treatment of adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.Talaramab-dlle is a bispecific T-cell engager that...

To read the full article, sign in and subscribe to AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS .

Thank you for choosing Find-A-Code, please Sign In to remove ads.